Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
Kim, K.H., Maderna, A., Schnute, M.E., Hegen, M., Mohan, S., Miyashiro, J., Lin, L., Li, E., Keegan, S., Lussier, J., Wrocklage, C., Nickerson-Nutter, C.L., Wittwer, A.J., Soutter, H., Caspers, N., Han, S., Kurumbail, R., Dunussi-Joannopoulos, K., Douhan, J., Wissner, A.(2011) Bioorg Med Chem Lett 21: 6258-6263
- PubMed: 21958547 
- DOI: https://doi.org/10.1016/j.bmcl.2011.09.008
- Primary Citation of Related Structures:  
3T9T - PubMed Abstract: 
Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The syntheses and SAR of this series of compounds are presented as well as the X-ray crystal structure of the lead compound 36 in complex with a gate-keeper variant of ITK enzyme. The lead compound showed good in vivo efficacy in preclinical RA models.
Organizational Affiliation: 
Medicinal Chemistry, Pfizer, 200 Cambridge Park Drive, Cambridge, MA 02140, United States. khkim87@hotmail.com